PharmTech Drug Digest 11.20
|Articles|April 7, 2014

Merck Announces Management Changes

Author(s)Melanie Sena

Merck promotes internal managers to head Merck Millipore and Consumer Health Divisions.

Merck KGaA

reported the promotion of three internal managers to head the life-science-tools and consumer health divisions as well as its allergy business unit as part of its “Fit for 2018” program.

Udit Batra, who previously managed Consumer Health, will become president and CEO of the Life Science Tools division, succeeding Robert Yates, who has left the company. Uta Kemmerich-Keil, currently CEO of Allergopharma and head of the global allergy business unit, will succeed Batra in his role as president and CEO of Consumer Health. Kemmerich-Keil will be replaced at Allergopharma by Marco Linari, who was head of the Operating Model within Merck Millipore and Performance Materials. All changes will take effect May 15.

In addition, Merck Serono President and CEO Belén Garijo will take charge of the R&D organization ad interim while the search for a permanent leader for the R&D organization is conducted. Annalisa Jenkins, who served in that role, left the company at the end of March.

Source:

Merck KGaA


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.